Acorn Wealth Advisors’s Epizyme, Inc EPZM Stock Holding History

Acorn Wealth Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-100	Closed	-$1K	–	810
2018 Q1	$1K	Hold	100	–	–	﹤0.01%	835
2017 Q4	$1K	Buy	+100	New	+$1.45K	﹤0.01%	797

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Acorn Wealth Advisors's EPZM Position: Q2 2018 in Review

Acorn Wealth Advisors sold out of Epizyme, Inc (EPZM) in Q2 2018, closing a stake of 100 shares — an estimated $1K sold.

Acorn Wealth Advisors first reported a position in EPZM in Q4 2017 and held it in 2 quarters. The position peaked at $1K in Q1 2018. 109 funds tracked by Wall St. Rank hold EPZM as of Q2 2018.

Acorn Wealth Advisors reported no remaining Epizyme, Inc position as of Q2 2018 after selling out during the quarter.
Acorn Wealth Advisors sold 100 Epizyme, Inc shares in Q2 2018, an estimated $1K.
Acorn Wealth Advisors first reported a position in Epizyme, Inc in Q4 2017 and held it in 2 quarters.
Acorn Wealth Advisors's Epizyme, Inc position peaked at $1K in Q1 2018.
109 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2018.

Based on Acorn Wealth Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.